Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 6/20 | 0.49 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681488 | 1.00 | GPR119 (0.50) | GPR119TRIM24BRPF1DHODHHRH3 | |
| SCHEMBL30681529 | 0.95 | GPR119 (0.48) | GPR119TRIM24BRPF1DHODHHRH3 | |
| SCHEMBL30681257 | 0.92 | GPR119 (0.46) | GPR119TRIM24BRPF1DHODHNAMPT | |
| SCHEMBL30681459 | 0.90 | CHRM4 (0.48) | GPR119TRIM24BRPF1HRH3NAMPT | |
| SCHEMBL10447445 | 0.90 | CHRM4 (0.48) | GPR119TRIM24BRPF1HRH3NAMPT | |
| SCHEMBL30681277 | 0.89 | GPR119 (0.46) | GPR119TRIM24BRPF1DHODHNOTUM | |
| SCHEMBL30681412 | 0.89 | GPR119 (0.47) | GPR119TRIM24DHODHNOTUMABHD6 | |
| SCHEMBL31599439 | 0.87 | GPR119 (0.45) | GPR119TRIM24BRPF1DHODHABHD6 | |
| SCHEMBL30681360 | 0.85 | CHRM4 (0.47) | GPR119TRIM24HRH3NAMPTNOTUM | |
| SCHEMBL30681369 | 0.82 | CHRM4 (0.45) | GPR119TRIM24NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| CN-111471037-B | Allylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-02-10 | — | — | CN | disclosed |
| CN-111471037-A | Allylamine compound and application thereof | 南京药捷安康生物科技有限公司 | 2020-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | GPR119 4453/4885TRIM24 738/4885BRPF1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.